Tailored Supplemental Screening for Breast Cancer: What Now and What Next?

被引:116
|
作者
Berg, Wendie A. [1 ]
机构
[1] Amer Radiol Serv, Dept Radiol, Lutherville Timonium, MD 21093 USA
关键词
breast cancer screening; breast imaging; breast MRI; breast sonography; gamma imaging; mammography; PET; HIGH FAMILIAL RISK; MUTATION CARRIERS; DENSE BREASTS; GENETIC PREDISPOSITION; DIGITAL MAMMOGRAPHY; COST-EFFECTIVENESS; BRCA2; MUTATION; FOLLOW-UP; WOMEN; ULTRASOUND;
D O I
10.2214/AJR.08.1706
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. This article reviews breast cancer risk assessment and the rationale for current screening guidelines, including when to consider using supplemental screening with MRI or sonography in addition to mammography, and discusses other emerging technologies. Radiologists can help identify women who may benefit from supplemental screening and can help to recommend when and which techniques to perform for this additional screening. CONCLUSION. Mammography remains the mainstay of breast cancer screening. Mammography should be performed as digital imaging when possible in women with dense breasts. In women at high risk, particularly if they also have dense breasts, annual MRI is recommended, although further validation of outcomes is needed. In intermediate-risk women with dense breasts, especially those with other risk factors, and in high-risk women with dense breasts who are unable to tolerate MRI, supplemental sonography screening is an option at facilities with availability of qualified personnel. Developing technologies are not appropriate for screening at this time, although further study is encouraged.
引用
下载
收藏
页码:390 / 399
页数:10
相关论文
共 50 条
  • [41] Research on sepsis biomarkers in the emergency department: What now, what next?
    Philippon, Anne-Laure
    Freund, Yonathan
    EMERGENCIAS, 2019, 31 (05): : 302 - 303
  • [42] New religious movements and science: What now, what next, where to?
    Bigliardi, Stefano
    Chin, Adam J.
    RELIGION COMPASS, 2024, 18 (04):
  • [43] FGFR inhibitors in cholangiocarcinoma: what's now and what's next?
    Saborowski, Anna
    Lehmann, Ulrich
    Vogel, Arndt
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [44] The G8 and global health - What now? What next?
    Labonte, R
    Schrecker, T
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2006, 97 (01): : 35 - 38
  • [45] Ebstein anomaly review: what's now, what's next?
    Dearani, Joseph A.
    Mora, Bassem N.
    Nelson, Timothy J.
    Haile, Dawit T.
    O'Leary, Patrick W.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (10) : 1101 - 1109
  • [46] BIOMARKERS OF CFTR TRANSDUCTION: WHAT'S NOW, WHAT'S NEXT?
    Clancy, John P.
    PEDIATRIC PULMONOLOGY, 2019, 54 : S51 - S53
  • [47] Small Incision Lenticule Extraction (SMILE): What Now? What Next?
    Randleman, J. Bradley
    OPHTHALMOLOGY, 2020, 127 (08) : 1035 - 1036
  • [48] Breast Cancer With Positive Sentinel Lymph Node: Now What?
    Morris, Gloria J.
    Berger, Adam C.
    Emanuelson, Richard G.
    Jordan, W. Edward, III
    McGuire, Kandace
    Thomas, Lisa C.
    SEMINARS IN ONCOLOGY, 2009, 36 (02) : 84 - 89
  • [49] Delays in screening What to do now?
    Theriault, Guylene
    CANADIAN FAMILY PHYSICIAN, 2022, 68 (12) : 882 - 884
  • [50] Debating Brexit: Why Now and What Next?
    Lennox, Rob
    Shepherd, Nick
    HISTORIC ENVIRONMENT-POLICY & PRACTICE, 2017, 8 (03): : 173 - 180